Name: BPC-157
Brand: ACE Peptides
Price: 2100 PHP
Availability: InStock
Rating: 5 (1 reviews)

The Science

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — 15 amino acids in sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — derived from a partial sequence of a protein found in human gastric juice. First isolated and studied by Dr. Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s, it has generated one of the most extensive preclinical research profiles of any peptide in existence.

As of mid-2026, the published literature contains over 212 peer-reviewed studies examining BPC-157 across virtually every organ and tissue system — musculoskeletal healing, gastrointestinal protection, neurological function, wound repair, inflammatory modulation, angiogenesis, cardiovascular research and more. The breadth and consistency of effects across independent research groups is what makes BPC-157 so scientifically compelling.

The honest picture on human evidence: in February 2026, Hudson Biotech began recruiting for the first properly designed randomised controlled trial of BPC-157 in humans — a Phase 2 trial that the research community has been waiting three decades for. Until those results are published, the human evidence base consists of three small pilot studies (IV safety pilot, n=2, Lee & Burgess 2025; knee pain retrospective, n=16, 87.5% relief at 6–12 months; interstitial cystitis, n=12, 80–100% symptom resolution) and a Phase 2 IBD trial with unpublished results. The preclinical case is extraordinary. The controlled human verdict is pending.

212+

Preclinical studies

Most across multiple independent research groups

15

Amino acids

Gastric protein-derived pentadecapeptide · Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

2026

First RCT recruiting

Hudson Biotech Phase 2 — the trial the field has been waiting for

Mechanisms of Action

How BPC-157 works — four converging pathways

A 2026 narrative review in the International Journal of Molecular Sciences (PMID 40789979) mapped BPC-157's mechanisms of action across the musculoskeletal healing literature. The authors identified four converging biological pathways — and noted that this convergence is precisely why BPC-157 shows reproducible effects across very different injury models and tissue types.

🩸

VEGFR2 — Angiogenesis

BPC-157 upregulates VEGF and its receptor (VEGFR2), driving the formation of new blood vessels into damaged tissue. This is the most critical mechanism for healing avascular or poorly vascularised tissues like tendons, ligaments and cartilage — structures that heal slowly precisely because they have limited blood supply. Without oxygen and nutrients delivered by new capillaries, collagen turnover cannot proceed.

→ New capillary formation into damaged tissue

⚡

eNOS — Nitric Oxide System

BPC-157 modulates nitric oxide synthesis via endothelial NOS (eNOS) and inducible NOS (iNOS) in a context-dependent, bidirectional manner — increasing NO when protective perfusion is needed, decreasing it when excess NO is driving chronic inflammation or cytotoxic damage. An independent Taiwanese research group showed BPC-157 directly disrupts the Cav-1–eNOS inhibitory complex, promoting NO production in aortic tissue in a dose-dependent manner.

→ Vascular protection and inflammation modulation

🔬

ERK1/2 — Proliferative Signalling

Extracellular signal-regulated kinases 1 and 2 carry proliferative signals in fibroblasts, tenocytes and epithelial cells — the cell types responsible for laying down new collagen and regenerating tissue architecture after injury. BPC-157's ERK1/2 activation is documented across wound healing, gut epithelial repair and tendon fibroblast studies.

→ Fibroblast and tenocyte proliferation for collagen

🛡️

Anti-Inflammatory Modulation

BPC-157 suppresses pro-inflammatory cytokine expression including IL-6 and TNF-alpha — not by blanket immune suppression, but by removing the inflammatory brake that delays tissue repair while preserving the immune response needed for pathogen clearance. This balance between necessary and harmful inflammation is what allows healing to proceed without compromising defence.

→ Controlled inflammation removal to enable repair

🏃

FAK-Paxillin — Cell Migration

BPC-157 activates focal adhesion kinase (FAK) and paxillin — two proteins essential for cell migration and adhesion. This pathway drives the movement of repair cells (fibroblasts, satellite cells, epithelial cells) into the wound bed — a prerequisite for healing that must occur before proliferation can begin. The FAK-paxillin mechanism is particularly relevant to gut epithelial repair and wound closure.

→ Repair cell migration into the wound bed

📈

Growth Hormone Receptor Upregulation

A cDNA microarray study in tendon fibroblasts identified Growth Hormone Receptor as the most abundantly upregulated gene after BPC-157 treatment — a 2.29-fold increase. This GH receptor upregulation amplifies the anabolic signalling of endogenous growth hormone at the tissue level, independently of GH secretion — which is why BPC-157 stacks particularly well with Ipamorelin and GH secretagogues.

→ Local amplification of GH signalling in target tissue

Research Areas

What 212+ studies have found

The 2026 AAOS systematic review (DeFoor & Dekker, Arthroscopy 2025) examined 22 preclinical mechanism studies and 15 musculoskeletal healing studies for BPC-157, finding consistent positive effects across four muscle transection/crush models and tendon repair models. A March 2026 review in the International Journal of Molecular Sciences (MDPI) — "From Regeneration to Analgesia" — consolidated the full evidence base across tissue types.

🦴

Tendon & Ligament Repair

The most extensively studied application. VEGFR2 upregulation drives capillary ingrowth into avascular tendon tissue — the fundamental barrier to tendon healing. Multiple Achilles tendon transection models show BPC-157 treated animals recover tensile strength and motor function significantly faster than controls. FAK-paxillin activation drives tenocyte migration into the repair site. GH receptor upregulation amplifies local anabolic signalling. The 2026 narrative review calls these findings the most mechanistically compelling in the musculoskeletal peptide literature.

💪

Muscle Repair & Recovery

Four preclinical muscle transection and crush models show BPC-157 improves load to failure, motor function indices, and muscle myofibril and macroscopic diameters versus controls. BPC-157 has also been shown to counteract tumour cachexia-driven muscle wasting and correct deranged muscle proliferation and myogenesis — extending its muscle research relevance beyond simple injury models to systemic muscle atrophy contexts.

🫁

Gastrointestinal Protection

The original research rationale for BPC-157 — it was discovered in gastric juice proteins. BPC-157 directly penetrates gut epithelium to reach intracellular repair targets without systemic circulation. A Phase 2 IBD trial (Pliva Pharmaceuticals) was registered but results not yet published as of July 2026. Preclinical data covers ulcerative colitis, anastomosis healing, liver cirrhosis reversal, portal hypertension counteraction, and gut-brain axis modulation.

🧠

Neurological & Gut-Brain Axis

Growing body of research examining BPC-157 in dopaminergic system modulation, traumatic brain injury models, peripheral nerve regeneration and gut-brain axis interactions. The peptide's ability to modulate the NO system and FAK-paxillin pathway has relevance in neural tissue — where cell migration and inflammation control are critical to recovery from neurological injury.

🩹

Wound & Skin Healing

Collagen synthesis, fibroblast proliferation, angiogenesis and anti-inflammatory action combine for comprehensive wound healing effects. The March 2026 MDPI review specifically noted BPC-157's application in burns, skin injuries and soft tissue damage. Corneal ulcer research showed an additional property: suppression of pathological neovascularisation (blood vessel overgrowth) while promoting beneficial healing angiogenesis — an important distinction for avascular tissue research.

🫀

Cardiovascular Research

Preclinical studies show protective effects on cardiac and smooth muscle. The NO system modulation has direct cardiovascular implications — promoting protective vascular function while suppressing the cytotoxic NO effects that accompany ischaemia and chronic inflammation. BPC-157 has been studied in arrhythmia, hypertension and cardiac injury models.

🦷

Bone & Periodontal Research

BPC-157's angiogenic and fibroblast-activating mechanisms extend to bone healing and periodontal tissue research. Studies examine its role in fracture healing acceleration, bone density support and periodontal ligament repair — tissues that share BPC-157's common requirement for angiogenesis and fibroblast-driven matrix reconstruction.

🔥

Anti-Tumour Research (emerging)

Recent publications note BPC-157 exhibits an anti-tumour effect in human melanoma cell lines by inhibiting VEGF's tumour-promoting effects. In mice with C26 colon adenocarcinoma, BPC-157 counteracted tumour cachexia, corrected muscle wasting, and markedly prolonged survival. These findings address the theoretical concern that VEGF upregulation could promote tumour growth — the data suggests the opposite in studied models.

2026 Milestone

The human trial the field has been waiting for

🔬

February 2026 — First Properly Designed Randomised Controlled Trial Now Recruiting

Hudson Biotech began recruiting for the first randomised, placebo-controlled, blinded trial of BPC-157 in humans in February 2026 — a Phase 2 study that represents the pivotal transition from preclinical to clinical evidence. For 30 years, BPC-157's research profile has been defined by the asymmetry between extraordinary preclinical breadth (212+ studies) and extremely limited human data. This trial is the mechanism by which that asymmetry begins to close.

🧬

Existing Human Pilot Data (2021–2025)

Three published human pilot studies as of July 2026 — all small, uncontrolled, but directionally consistent. IV Safety Study (Lee & Burgess, 2025, PMID 40131143): Two healthy adults received up to 20mg IV. Cardiac, hepatic, renal, thyroid and glucose biomarkers showed no adverse change — the foundational safety reference for future IV human work. Knee pain retrospective (2021, n=16): 87.5% of patients reported significant relief at 6–12 month follow-up after intra-articular BPC-157 injection. Interstitial cystitis (2024, n=12): 80–100% symptom resolution with bladder injections. No randomised controlled trial data exists yet — these are hypothesis-generating, not confirmatory.

⚖️

Regulatory Status — FDA Category 2, PCAC Review July 2026

BPC-157 is currently FDA Category 2 — meaning it cannot be legally compounded in the United States due to insufficient safety data for the FDA's compounding standards. The Pharmacy Compounding Advisory Committee (PCAC) has scheduled BPC-157 for formal review in July 2026. Multiple compounding pharmacies and research groups have submitted citizen petitions for reclassification to Category 1. If reclassified, BPC-157 would become one of the most prescribed compounded peptides given existing research demand. All ACE Peptides products are supplied for research purposes only.

Stack Synergies

How BPC-157 works with other ACE compounds

BPC-157's distinct mechanisms make it a powerful foundation for research stacks. Here's the mechanistic logic for the three most studied combinations:

🐺 The Wolverine Stack — BPC-157 + TB-500

The most researched healing peptide combination. BPC-157 + TB-500 — two independent mechanisms with zero overlap for comprehensive acute repair coverage.

💊

BPC-157 — The Repair Engine

VEGFR2 angiogenesis · eNOS protection · ERK1/2 proliferation · FAK-paxillin migration

YOU ARE HERE

⚡

TB-500 — Cell Migration Driver

Actin cytoskeleton modulation · G-actin sequestration · Cardiac regeneration · Systemic anti-inflammatory

VIEW →

Why they work together: BPC-157 drives angiogenesis via VEGFR2 and cell migration via FAK-paxillin. TB-500 drives cell migration via G-actin sequestration and angiogenesis via VEGF — different pathways, zero overlap, fully additive. Want to extend to collagen matrix rebuild? Add GHK-Cu to build the GLOW Stack.

✨ The GLOW Stack — BPC-157 + TB-500 + GHK-Cu

Add TB-500 + GHK-Cu to BPC-157 for the full GLOW Stack. BPC-157 clears the inflammatory environment. TB-500 drives additional cell migration via G-actin. GHK-Cu then activates 4,192 genes for collagen synthesis, elastin, hair growth and antioxidant defence — the complete skin, hair and tissue regeneration protocol.

📈 BPC-157 + Retatrutide — Metabolic Repair Protocol

An emerging research area: Retatrutide's rapid fat loss (28.3% mean reduction in TRIUMPH-1) creates a body composition change that can accelerate the healing of weight-bearing joints and tendons previously stressed by excess load. BPC-157's VEGFR2 angiogenesis mechanism is particularly relevant to the joint and connective tissue healing that often accompanies significant weight reduction. The two compounds address completely different biological systems — metabolic and structural — making them non-competing companions in comprehensive body transformation and recovery research.

Research Protocol

Suggested research protocol

1

Reconstitution

Add 2ml bacteriostatic water to a 10mg vial for a concentration of 5mg/ml (5,000mcg/ml). For easier micro-dosing, add 5ml for 2mg/ml (2,000mcg/ml). Always inject BAC water slowly down the side of the vial — not directly onto the powder. Gently swirl; never shake. Use the ACE Peptides reconstitution calculator for exact syringe marks.

2

Dose range studied

Animal-to-human extrapolation suggests 200–500mcg per injection as the most commonly studied range. The human pilot knee pain study used 2,000mcg intra-articular. The IV safety study tested up to 20,000mcg (20mg) without adverse events. Most subcutaneous protocols use 250–500mcg per injection.

3

Frequency & duration

Research protocols vary from once daily to twice daily injection. Common cycle lengths: 4–8 weeks continuous. Some researchers prefer localised injection near the target tissue site for musculoskeletal applications; systemic subcutaneous injection for gastrointestinal or systemic research objectives.

4

Storage

Unreconstituted: −20°C indefinitely. Reconstituted: +4°C refrigerated for up to 28 days. Keep away from light and heat. Do not freeze the reconstituted solution. BPC-157 is relatively stable — the lyophilised powder maintains integrity well at −20°C for extended periods.

FAQ

Frequently asked questions

What is included in the kit?

Every BPC-157 order from ACE Peptides includes a complete research kit: a drawing syringe for reconstitution, insulin syringes for injection, alcohol pads, 3ml of bacteriostatic water (BAC water), and secure discreet packaging. Everything you need is included.

Can I buy just the peptide vial without the kit?

Yes — if you already have your own supplies, just let us know via WhatsApp and we'll accommodate you. Contact us via WhatsApp →

What does BPC stand for?

Body Protection Compound. It was named for its broad cytoprotective properties observed across multiple organ systems in preclinical research — the gastric protein from which it was derived appears to protect stomach tissue from acid damage, and the researchers extrapolated that protection capacity to the synthetic 15-amino acid fragment.

Is BPC-157 better for subcutaneous or localised injection?

Research suggests both routes are effective, but with different applications. Subcutaneous injection in the abdomen is used for systemic effects — gut healing, systemic anti-inflammatory action, neurological research. Localised injection near target tissue (a damaged tendon, joint, muscle) is used in musculoskeletal repair research where proximity to the injury site may enhance local angiogenesis and fibroblast activation. The human knee pain pilot used intra-articular injection.

How does BPC-157 work with TB-500 in the Wolverine Stack?

They are mechanistically complementary with no functional overlap. BPC-157 drives angiogenesis via VEGFR2, proliferative signalling via ERK1/2, and cell migration via FAK-paxillin. TB-500 drives cell migration via a completely different mechanism — G-actin sequestration and actin cytoskeleton modulation. Together they provide redundant cell migration pathways, combined angiogenesis and anti-inflammatory coverage, making the stack more comprehensive than either alone. See the full TB-500 page and Wolverine Stack page.

Why is BPC-157 FDA Category 2?

The FDA's Category 2 classification reflects insufficient published human safety data for compounding purposes under 503A pharmacy regulations — not a finding of harm. The 2023 classification was based on the limited human trial data available at that time. A PCAC review is scheduled for July 2026, and multiple compounding groups have petitioned for Category 1 reclassification, citing the 2025 IV safety pilot (PMID 40131143) and growing clinical experience. All ACE Peptides products are for research purposes only.

Can I buy BPC-157 in the Philippines?

ACE Peptides supplies BPC-157 as a research compound across the Philippines — Manila, Cebu, Davao, Siargao and all major cities and provinces. Enquiries handled via WhatsApp, discreet nationwide shipping, fast dispatch. All products are for research purposes only.

How do I calculate my dose?

Use the free ACE Peptides reconstitution calculator. Enter your vial size (10mg), how much BAC water you added, and your desired dose in mcg. The calculator gives you the exact syringe mark — no maths required.

References

Research sources

DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides — An Adjunct to Regenerative Medicine and Sports Performance? Arthroscopy. 2025;41:150–152. AAOS 2025 systematic review: 22 mechanism studies, 15 musculoskeletal studies.

MDPI Int J Mol Sci. "From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management." Published March 22, 2026. doi:10.3390/ijms27062876

PMID 40789979. BPC-157 narrative review — musculoskeletal healing, four mechanism pillars: VEGFR2, eNOS, ERK1/2, anti-inflammatory. April 25, 2026.

Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31:20–24. PMID: 40131143

PMC12567428. Sikiric P, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals. 2026. (Reply to Jozwiak et al. review)

Sikiric P, et al. BPC 157 angiogenesis in muscle and tendon healing — VEGF, CD34, FVIII immunohistochemical analysis. J Orthop Res. 2010. PMID: 20388964

Chang CH, et al. Growth hormone receptor upregulation in tendon fibroblasts by BPC 157 — cDNA microarray analysis. Molecules. 2014;19:19066–19077. PMC6271067

PeptIQ. "BPC-157 Hits a Milestone: The First Controlled Human Trial Is Now Recruiting." May 14, 2026. Hudson Biotech Phase 2 RCT begins recruiting.

PeptideMark. "BPC-157 Human Trials: What the Evidence Shows (2026)." Updated May 17, 2026.

Complete your protocol

BPC-157